These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34162033)

  • 21. Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits.
    Myers SE; Whitman BY; Carrel AL; Moerchen V; Bekx MT; Allen DB
    Am J Med Genet A; 2007 Mar; 143A(5):443-8. PubMed ID: 17103437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Visceral adipose tissue increases shortly after the cessation of GH therapy in adults with Prader-Willi syndrome.
    Koizumi M; Ida S; Shoji Y; Nishimoto Y; Etani Y; Kawai M
    Endocr J; 2018 Nov; 65(11):1127-1137. PubMed ID: 30185718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subcutaneous adipose tissue is a positive predictor for bone mineral density in prepubertal children with Prader-Willi syndrome independent of lean mass.
    Kawai M; Etani Y; Ida S
    J Pediatr Endocrinol Metab; 2022 May; 35(5):603-609. PubMed ID: 35286052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating insulin-like growth factor 1 levels are reduced in very young children with Prader-Willi syndrome independent of anthropometric parameters and nutritional status.
    Koizumi M; Konishi A; Etani Y; Ida S; Kawai M
    Clin Endocrinol (Oxf); 2022 Mar; 96(3):346-352. PubMed ID: 34750859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably.
    Lindgren AC; Hagenäs L; Müller J; Blichfeldt S; Rosenborg M; Brismar T; Ritzén EM
    Acta Paediatr; 1998 Jan; 87(1):28-31. PubMed ID: 9510443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of genetic subtypes and growth hormone treatment on bone mineral density in Prader-Willi syndrome.
    Khare M; Gold JA; Wencel M; Billimek J; Surampalli A; Duarte B; Pontello A; Galassetti P; Cassidy S; Kimonis VE
    J Pediatr Endocrinol Metab; 2014 May; 27(5-6):511-8. PubMed ID: 24515997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thyroid hormone levels in children with Prader-Willi syndrome: a randomized controlled growth hormone trial and 10-year growth hormone study.
    Trueba-Timmermans DJ; Grootjen LN; Kerkhof GF; Rings EHHM; Hokken-Koelega ACS
    Eur J Endocrinol; 2024 Aug; 191(2):126-133. PubMed ID: 39049789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth hormone treatment for osteoporosis in patients with scoliosis of Prader-Willi syndrome.
    Nakamura Y; Murakami N; Iida T; Asano S; Ozeki S; Nagai T
    J Orthop Sci; 2014 Nov; 19(6):877-82. PubMed ID: 25257562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.
    Myers SE; Carrel AL; Whitman BY; Allen DB
    J Pediatr; 2000 Jul; 137(1):42-9. PubMed ID: 10891820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
    Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects.
    Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Schroor EJ; Van Alfen AA; Van Leeuwen M; Van Pinxteren-Nagler E; Van Wieringen H; Vreuls RC; Zwaveling-Soonawala N; de Ridder MA; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2013 Oct; 98(10):4013-22. PubMed ID: 24001750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome.
    Dağdeviren Çakır A; Baş F; Akın O; Şıklar Z; Özcabı B; Berberoğlu M; Kardelen AD; Bayramoğlu E; Poyrazoğlu Ş; Aydın M; Törel Ergür A; Gökşen D; Bolu S; Aycan Z; Tüysüz B; Ercan O; Evliyaoğlu O
    J Clin Res Pediatr Endocrinol; 2021 Aug; 13(3):308-319. PubMed ID: 33565750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cognitive functioning in children with Prader-Willi syndrome during 8 years of growth hormone treatment.
    Donze SH; Damen L; Mahabier EF; Hokken-Koelega ACS
    Eur J Endocrinol; 2020 Apr; 182(4):405-411. PubMed ID: 31961800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in Bone Metabolism between Children with Prader-Willi Syndrome during Growth Hormone Treatment and Healthy Subjects: A Pilot Study.
    Gajewska J; Chełchowska M; Szamotulska K; Klemarczyk W; Strucińska M; Ambroszkiewicz J
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low dose growth hormone treatment in infants and toddlers with Prader-Willi syndrome is comparable to higher dosage regimens.
    Scheermeyer E; Harris M; Hughes I; Crock PA; Ambler G; Verge CF; Bergman P; Werther G; Craig ME; Choong CS; Davies PSW;
    Growth Horm IGF Res; 2017 Jun; 34():1-7. PubMed ID: 28427039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Pediatr; 1999 Feb; 134(2):215-21. PubMed ID: 9931532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment.
    Höybye C
    Growth Horm IGF Res; 2004 Feb; 14(1):1-15. PubMed ID: 14700552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thyroid hormone levels in children with Prader-Willi syndrome before and during growth hormone treatment.
    Festen DA; Visser TJ; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):449-56. PubMed ID: 17716335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Final adult height in children with Prader-Willi syndrome with and without human growth hormone treatment.
    Angulo MA; Castro-Magana M; Lamerson M; Arguello R; Accacha S; Khan A
    Am J Med Genet A; 2007 Jul; 143A(13):1456-61. PubMed ID: 17567883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of Circulating Mediators of Bone Remodeling in Prader-Willi Syndrome.
    Brunetti G; Grugni G; Piacente L; Delvecchio M; Ventura A; Giordano P; Grano M; D'Amato G; Laforgia D; Crinò A; Faienza MF
    Calcif Tissue Int; 2018 Jun; 102(6):635-643. PubMed ID: 29353451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.